Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather busy. We plan to escort Mrs. Pharmalot to a rent party, accompany one of our short people on a charity mission, and catch up on our reading. And what about you? This is a fine time to enjoy the great outdoors or visit someone special. Perhaps you need to tidy up around your castle. Whatever you do, have a grand time. But be safe. See you soon …

A lobbyist warned that it will be challenging to uphold a tax break that allows drug makers to write off money they spend on advertising and marketing, Medical Marketing & Media reports. A Senate bill was proposed in March to end the deduction and it will be “one of the hardest things to defend,” Jim Davidson, chair of the the Advertising Tax Coalition, told an industry conference.


Harvard Medical School is loosening some conflict-of-interest rules that currently prevent research scientists from doing work on clinical trials for companies in which they have a financial interest, at least in some situations, according to STAT. The school is raising thresholds on how much income or equity researchers have in a public company before they are barred from doing clinical research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • From the second article referenced in Dinesh T item – ‘Sun Pharmaceutical Industries said it isn’t aware of any adverse findings related to the manufacturing plants…’ AND no doubt they will be ‘shocked, shocked to hear there was gambling in this establishment.’ (Apologies to Casablanca)

Comments are closed.